Navigation Links
Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today announced that S. Wayne Kay, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at 10:20 a.m. Eastern time at The New York Palace Hotel in New York City.

A Web cast of the presentation will be available at http://wsw.com/webcast/rrshq14/rbm.cn, during the event and will be archived and available on a link through the corporate Web site (http://www.responsebio.com) for 90 days.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack and congestive heart failure.

In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests worldwide and in 2008 entered into a strategic alliance with Roche Diagnostics to commercialize rapid cardiovascular tests worldwide.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at http://www.responsebio.com.


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Response Biomedical Closes $5.1 Million Financing
2. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
3. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
4. Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing
5. Response Biomedical Announces Insider Participation in Current Financing
6. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
7. Monitoring immune responses in disease
8. Gustav: World Vision Teams Assist Evacuees in Jackson and Dallas, Prepare Response
9. Immune Response May Hinder Stem Cell Treatments
10. Study sees need for standardized evaluation of antibody response to HIV-1
11. Presidents Award Recognizes Hospitals Response to Bridge Collapse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... 2017 , ... Children and adolescents who enter the foster ... in the general population. That’s because foster care is designed to protect children ... no fault of their own, youth who have experienced trauma often have difficulty ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain company ... Tina Howe joined the team, the Bill Howe brand was born and they began ... and giving back to the San Diego community in which they worked, lived and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation ... supplements, through its Nova Skin Sciences division, recently announced the launch of Allumière ... with the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group leased ... is developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company ... life-threatening diseases that have been underserved by scientific ... therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: